CN Patent

CN103649103A — 用于抑制载脂蛋白c-iii(apoc3)基因表达的组合物与方法

Assigned to Alnylam Pharmaceuticals Inc · Expires 2014-03-19 · 12y expired

What this patent protects

本发明涉及靶向APOC3基因的双链核糖核酸(dsRNA)、以及使用该dsRNA抑制APOC3表达的方法。

USPTO Abstract

本发明涉及靶向APOC3基因的双链核糖核酸(dsRNA)、以及使用该dsRNA抑制APOC3表达的方法。

Drugs covered by this patent

donidalorsen-sodium (DONIDALORSEN SODIUM)

Patent Metadata

Patent number: CN103649103A
Jurisdiction: CN
Classification: —
Expires: 2014-03-19
Drug substance claim: No
Drug product claim: No
Assignee: Alnylam Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.